Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

KalVista Pharmaceuticals (KALV) Income towards Parent Company (2016 - 2025)

KalVista Pharmaceuticals' Income towards Parent Company history spans 11 years, with the latest figure at $39.4 million for Q2 2025.

  • On a quarterly basis, Income towards Parent Company rose 34.35% to $39.4 million in Q2 2025 year-over-year; TTM through Apr 2025 was -$45.5 million, a 19.97% increase, with the full-year FY2025 number at -$91.8 million, down 74.34% from a year prior.
  • Income towards Parent Company hit $39.4 million in Q2 2025 for KalVista Pharmaceuticals, up from -$44.5 million in the prior quarter.
  • Over the last five years, Income towards Parent Company for KALV hit a ceiling of $39.4 million in Q2 2025 and a floor of -$44.5 million in Q4 2024.
  • Historically, Income towards Parent Company has averaged -$14.4 million across 4 years, with a median of -$28.6 million in 2023.
  • Biggest five-year swings in Income towards Parent Company: plummeted 53.45% in 2024 and later skyrocketed 34.35% in 2025.
  • Tracing KALV's Income towards Parent Company over 4 years: stood at -$12.5 million in 2021, then tumbled by 131.39% to -$29.0 million in 2023, then plummeted by 53.45% to -$44.5 million in 2024, then skyrocketed by 188.65% to $39.4 million in 2025.
  • Business Quant data shows Income towards Parent Company for KALV at $39.4 million in Q2 2025, -$44.5 million in Q4 2024, and -$40.4 million in Q3 2024.